List of Excipients in Branded Drug TRIZIVIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ViiV Healthcare Company	TRIZIVIR	abacavir sulfate, lamivudine, and zidovudine	49702-217	CELLULOSE, MICROCRYSTALLINE
ViiV Healthcare Company	TRIZIVIR	abacavir sulfate, lamivudine, and zidovudine	49702-217	FD&C BLUE NO. 2
ViiV Healthcare Company	TRIZIVIR	abacavir sulfate, lamivudine, and zidovudine	49702-217	FERRIC OXIDE YELLOW
ViiV Healthcare Company	TRIZIVIR	abacavir sulfate, lamivudine, and zidovudine	49702-217	HYPROMELLOSE
ViiV Healthcare Company	TRIZIVIR	abacavir sulfate, lamivudine, and zidovudine	49702-217	MAGNESIUM STEARATE

Trizivir Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Trizivir is a fixed-dose combination tablet containing abacavir sulfate, lamivudine, and zidovudine. Its excipient strategy is commercially important because the product combines a high active load, three chemically distinct nucleoside reverse transcriptase inhibitors, immediate-release performance requirements, and a legacy HIV market that has shifted toward dolutegravir-based regimens. The main opportunities are generic fixed-dose combination supply, excipient substitution, manufacturing-cost reduction, and reformulation for markets where Trizivir remains clinically relevant. Patent protection is no longer the primary barrier.

What is Trizivir and which active ingredients does it contain?

Trizivir is an oral, film-coated tablet containing:

Component	Amount per tablet
Abacavir, as abacavir sulfate	300 mg
Lamivudine	150 mg
Zidovudine	300 mg
Total active pharmaceutical ingredients	750 mg, excluding salt contribution

The product is administered as one tablet twice daily when prescribed. The U.S. product labeling identifies Trizivir as a prescription antiretroviral fixed-dose combination indicated for HIV-1 infection, subject to the limitations and warnings associated with its individual components [1].

Trizivir contains three small-molecule antiretroviral APIs. It is not a biologic and does not create biosimilar-specific regulatory or manufacturing issues.

What excipients are used in Trizivir tablets?

The U.S. prescribing information identifies the following tablet excipients:

• Microcrystalline cellulose
• Colloidal silicon dioxide
• Sodium starch glycolate
• Magnesium stearate

The film coating contains hypromellose, titanium dioxide, polyethylene glycol, and synthetic yellow iron oxide, according to the product labeling [1].

The formulation is consistent with a high-dose immediate-release tablet. Microcrystalline cellulose provides bulk and compaction support. Sodium starch glycolate promotes tablet breakup. Colloidal silicon dioxide improves powder flow and can reduce cohesion in a formulation containing multiple APIs. Magnesium stearate provides lubrication but requires control because excessive lubrication can reduce tablet tensile strength and slow dissolution.

How does Trizivir’s excipient strategy address formulation challenges?

Trizivir has a high total drug load and combines APIs with different physical and chemical properties. The excipient system must support powder flow, blend uniformity, tablet hardness, rapid disintegration, and dissolution across the three active ingredients.

High active load and tablet size

The active ingredients account for most of the tablet mass. That limits the amount of excipient available for:

• Flow enhancement
• Binding
• Disintegration
• Moisture control
• Taste and mouthfeel modification
• Compression-force adjustment

A generic manufacturer would need to preserve the required dose while avoiding an excessive tablet size. A material shift from conventional microcrystalline cellulose to a higher-functionality co-processed excipient could reduce process steps, but it would require comparative dissolution and stability data.

Blend uniformity

Lamivudine is present at half the mass of zidovudine and abacavir. Small differences in particle-size distribution, density, or electrostatic behavior can cause segregation during blending or tablet transfer. A robust generic process may require:

• API particle-size control
• Geometric dilution for lower-dose lamivudine
• Ordered mixing or granulation
• In-process blend uniformity testing
• Controlled lubricant addition

Excipient suppliers with engineered grades of microcrystalline cellulose, colloidal silicon dioxide, or co-processed fillers could compete on blend uniformity and manufacturing robustness rather than on composition ownership.

Disintegration and dissolution

Sodium starch glycolate is the primary disclosed superdisintegrant. Because the tablet contains 750 mg of active ingredients, disintegration may be sensitive to compression force, lubricant level, granule porosity, and storage humidity.

A substitution strategy could evaluate crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, or combinations of superdisintegrants. The commercial objective would be to match the reference product’s dissolution profile while improving:

• Disintegration consistency
• Compression speed
• Tablet hardness
• Resistance to capping and lamination
• Performance after accelerated storage

A substitute excipient does not require a new patent position by itself. Its value depends on demonstrating pharmaceutical equivalence and manufacturing advantages.

Lubrication and dissolution risk

Magnesium stearate is effective at low concentrations but can create dissolution and tablet-strength problems when overmixed or overused. A generic formulation could examine alternative lubricants such as sodium stearyl fumarate or improved magnesium stearate grades. Any change would require evaluation of:

• Ejection force
• Tablet tensile strength
• Disintegration time
• Dissolution across pH conditions
• Stability and impurity formation

The most defensible commercial opportunity is often process control rather than simply replacing magnesium stearate.

What FDA regulatory status does Trizivir have?

Trizivir was approved by the FDA in 2000 under NDA 021652 [1]. It is regulated as a small-molecule prescription drug. Generic versions would generally be developed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Regulatory attribute	Trizivir status
Active ingredients	Abacavir sulfate, lamivudine, zidovudine
Dosage form	Film-coated immediate-release tablet
U.S. NDA	021652
FDA approval	2000
Regulatory category	Small-molecule fixed-dose combination
Generic pathway	ANDA, subject to product-specific requirements
Biosimilar pathway	Not applicable
Key clinical safety issue	Abacavir hypersensitivity and HLA-B*5701 risk
Reference product holder	ViiV Healthcare-related HIV portfolio

The FDA label requires attention to abacavir hypersensitivity, including HLA-B*5701 testing before initiation where appropriate. The label also contains warnings associated with zidovudine and the combination’s mitochondrial, hematologic, hepatic, and lactic-acidosis risks [1].

When does Trizivir lose exclusivity and when did its patents expire?

Trizivir’s principal exclusivity barriers have expired. The relevant active-ingredient patent families are legacy patents associated with abacavir, lamivudine, and zidovudine.

Active ingredient	Representative U.S. patent	Approximate U.S. statutory expiry
Zidovudine	U.S. Patent No. 4,724,232	2005
Lamivudine	U.S. Patent No. 5,047,407	2009
Abacavir	U.S. Patent No. 5,034,394	2010

The exact enforceability timeline can be affected by patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and jurisdiction-specific rules. FDA Orange Book records, rather than the original patent issue date alone, control the practical analysis for ANDA certification [2].

No biosimilar barrier applies because Trizivir is not a biologic. The commercial question is therefore generic substitution and formulation execution, not biosimilar interchangeability.

What is the Orange Book status of Trizivir?

Trizivir has been listed in the FDA Orange Book as a prescription reference product under NDA 021652. Historical patent listings associated with the component products and combination product have reached expiry or no longer provide a meaningful U.S. market-exclusion period based on the public patent timeline [2].

A current ANDA applicant would still need to review the live Orange Book record, product-specific bioequivalence requirements, labeling requirements, and any relevant exclusivity codes before filing. An expired patent estate does not eliminate regulatory risk from bioequivalence failure or labeling noncompliance.

Are Paragraph IV challenges relevant to Trizivir?

Paragraph IV challenges were commercially relevant during the period when Trizivir-related patents remained listed and unexpired. They are less important today because the principal patent barriers have expired.

For a modern generic applicant, the likely certification analysis is:

1. Identify all currently listed patents for the reference product.
2. Determine whether each patent is expired, listed without enforceable scope, or subject to a live term.
3. File a Paragraph III certification for patents that have not expired but will expire before launch, or a Paragraph IV certification where a listed patent is invalid, unenforceable, or not infringed.
4. Assess whether any 180-day generic exclusivity has already been triggered or forfeited.

The absence of a major current patent barrier does not guarantee immediate generic launch. Manufacturing validation, API sourcing, bioequivalence, quality systems, and market economics are more significant barriers for Trizivir.

What formulation patents protect Trizivir?

The commercial formulation is protected primarily by the original product development, regulatory dossier, manufacturing know-how, and historical patent filings rather than by a durable current patent moat.

A generic applicant should assess four categories of intellectual property:

IP category	Current commercial relevance
Active-ingredient patents	Largely expired
Fixed-dose combination patents	Historical relevance; expiry must be confirmed against live records
Tablet and coating formulation patents	Potentially relevant only if an unexpired claim remains listed or enforceable
Manufacturing know-how	May remain commercially useful even without patent protection

Excipients themselves are generally off-patent commodities. The stronger IP opportunities would arise from a differentiated manufacturing process, a new solid-state form, an improved stability system, a novel dosage form, or a clinically meaningful modified-release formulation. Those approaches would carry higher development and regulatory costs than a conventional ANDA.

What commercial opportunities exist for Trizivir excipients?

Generic fixed-dose combination supply

The clearest opportunity is supplying excipients to manufacturers developing or maintaining generic abacavir/lamivudine/zidovudine tablets. Demand would likely center on:

• Direct-compression microcrystalline cellulose
• High-purity colloidal silicon dioxide
• Consistent sodium starch glycolate
• Low-moisture magnesium stearate
• Film-coating systems with controlled color and opacity

Suppliers can differentiate through global regulatory documentation, low extractables and leachables risk, compendial compliance, lot-to-lot consistency, and technical support.

Co-processed excipients

A co-processed filler-binder/disintegrant platform could reduce the number of unit operations in a generic manufacturing process. It may be attractive where the manufacturer uses direct compression and wants to avoid wet granulation.

Potential advantages include:

• Better flow at high drug loading
• Improved tablet tensile strength
• Lower sensitivity to compression speed
• More uniform disintegration
• Reduced formulation screening time

The supplier would need to show that the excipient does not alter dissolution, impurity profiles, assay uniformity, or stability.

Film-coating systems

The coating has lower strategic value than the core tablet but remains a practical supply opportunity. A ready-to-use coating system could provide:

• Consistent yellow coloration
• Shorter coating development time
• Improved process reproducibility
• Lower solvent or water burden
• Better protection against handling abrasion

Any coating change must preserve tablet identification and avoid interference with dissolution or stability.

Regional and public-sector procurement

Trizivir may retain demand in countries where treatment guidelines, procurement systems, or patient-specific treatment histories support its use. The market is likely to be strongest where:

• Generic procurement is price-sensitive
• Older antiretroviral regimens remain in treatment programs
• Patients require a multi-drug fixed-dose option
• Local regulatory pathways accept established reference formulations
• Supply continuity is valued over newer regimen adoption

The main constraint is clinical displacement by better-tolerated and more convenient integrase inhibitor-based regimens.

How does Trizivir compare with competing HIV fixed-dose combinations?

Trizivir’s commercial position is weaker than newer first-line fixed-dose combinations.

Product category	Core ingredients	Market position
Trizivir	Abacavir, lamivudine, zidovudine	Legacy triple-NRTI option; twice-daily dosing
Abacavir/lamivudine	Two-NRTI backbone	Simpler regimen; still limited by abacavir safety considerations
Dolutegravir/abacavir/lamivudine	Integrase inhibitor plus two NRTIs	More modern efficacy and dosing profile
Tenofovir-based combinations	Tenofovir plus companion agents	Broad use in contemporary guidelines
Long-acting antiretroviral regimens	Injectable agents	Compete on adherence and dosing frequency

Zidovudine-related anemia, neutropenia, mitochondrial toxicity, and twice-daily administration reduce Trizivir’s competitiveness. Abacavir requires additional clinical risk management because of hypersensitivity concerns. These factors limit the upside of premium excipient innovation.

Which companies are likely to challenge or supply Trizivir?

The relevant competitive groups are:

• Generic antiretroviral manufacturers with ANDA capabilities
• Contract manufacturers serving emerging markets
• Excipient producers with direct-compression platforms
• Film-coating suppliers
• API manufacturers producing abacavir sulfate, lamivudine, or zidovudine
• Public-sector procurement suppliers

The original HIV business associated with GlaxoSmithKline is now managed through ViiV Healthcare, the specialist HIV company established by GSK and Pfizer, with later participation by Shionogi [3]. Public disclosures generally do not provide standalone Trizivir revenue, so product-specific revenue exposure cannot be calculated reliably from company filings.

What licensing deals affect Trizivir?

The relevant corporate transaction is the transfer and consolidation of GSK’s HIV assets into ViiV Healthcare, rather than an excipient-specific licensing agreement. No publicly disclosed excipient license appears to create a material barrier to generic formulation development.

A licensee evaluating Trizivir would focus on:

• Territory-specific product rights
• Local registration ownership
• API and excipient supply commitments
• Pharmacovigilance responsibilities
• Government procurement eligibility
• Existing distribution agreements
• Any settlement or authorized-generic arrangement

The commercial value of a license is likely to depend more on geographic access and procurement relationships than on U.S. exclusivity.

What generic launch scenarios exist for Trizivir?

Low-cost conventional generic

This is the most credible scenario. The manufacturer uses compendial excipients closely aligned with the reference formulation, establishes bioequivalence, and competes on price and supply reliability.

Process-optimized generic

A manufacturer could use co-processed excipients or a redesigned granulation process to reduce manufacturing cost. The product would remain an immediate-release tablet but could have a distinct formulation composition.

Regional fixed-dose product

A regional manufacturer could target countries where Trizivir remains in treatment protocols or public-sector tenders. Regulatory reliance and local procurement rules may be more important than U.S. patent status.

505(b)(2) reformulation

A modified-release, dispersible, pediatric, or alternative dosage form could support a 505(b)(2) strategy if the product offers a meaningful clinical or administration advantage. This route would carry higher clinical, regulatory, and patent risk than an ANDA.

How strong is the Trizivir patent estate?

The current patent estate is weak as a market-exclusion tool. The key composition and active-ingredient patents are historical and expired. The remaining defensibility lies in:

• Product-specific regulatory data
• Manufacturing know-how
• Quality control systems
• Supply-chain reliability
• Trademark and brand recognition
• Market access and procurement contracts

For an excipient company, Trizivir is therefore a volume and technical-support opportunity, not a high-margin protected-product opportunity.

Key Takeaways

• Trizivir is a high-active-load immediate-release tablet containing abacavir sulfate, lamivudine, and zidovudine.
• Its disclosed excipients are microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, magnesium stearate, and film-coating materials.
• Excipient development should prioritize blend uniformity, tabletability, rapid disintegration, dissolution, and stability.
• The principal U.S. patent barriers expired between approximately 2005 and 2010, subject to applicable patent-term adjustments and extensions.
• Paragraph IV litigation is no longer the central commercial issue for a new generic applicant.
• Trizivir is not a biologic, so biosimilar risk is irrelevant.
• The strongest commercial opportunities are generic supply, co-processed excipients, film-coating systems, and regional procurement.
• Clinical displacement by dolutegravir- and tenofovir-based regimens limits long-term demand.
• No standalone Trizivir revenue figure is generally disclosed by ViiV or its parent companies.
• Manufacturing execution and market access are more important than patent exclusion.

FAQs

Can a generic Trizivir manufacturer change the excipients?

Yes. An ANDA applicant can use different inactive ingredients if the formulation meets applicable quality, bioequivalence, dissolution, stability, labeling, and safety requirements. The substitute excipients must not create new tolerability or manufacturing risks.

Is Trizivir eligible for a biosimilar application?

No. Trizivir contains small-molecule APIs and would be addressed through a generic drug pathway, generally an ANDA, rather than a biosimilar application.

Which excipient is most important for Trizivir tablet performance?

Microcrystalline cellulose is important for bulk and compaction, while sodium starch glycolate is central to disintegration. Their performance must be assessed together with magnesium stearate level, blending time, compression force, and tablet porosity.

Does Trizivir have meaningful U.S. patent protection today?

The principal historical active-ingredient and combination-product barriers have expired or reached the end of their practical exclusion period. A live Orange Book review remains necessary for any filing decision, but patent protection is not the principal current barrier.

Is a new Trizivir formulation commercially attractive?

A conventional generic may be commercially viable in selected markets. A premium reformulation is less attractive unless it solves a specific problem such as tablet size, dosing frequency, pediatric administration, stability, or access in resource-limited settings.

References

1. U.S. Food and Drug Administration. (2023). Trizivir (abacavir sulfate, lamivudine, and zidovudine) tablets: Prescribing information. ViiV Healthcare.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. ViiV Healthcare. (n.d.). About ViiV Healthcare. https://viivhealthcare.com/en-us/about-us/